B형 간염 바이러스(HBV) 카프시드 억제제 시장 보고서(2026년)

Hepatitis B virus (HBV) capsid inhibitors are a class of antiviral drugs that disrupt the assembly, disassembly, or stability of the viral capsid, crucial for HBV replication. They target the core protein that forms the protective shell around the viral DNA, blocking the creation of new infectious particles. Through interference with capsid formation, these inhibitors lower viral load and slow disease progression. HBV capsid inhibitors offer a promising strategy for reaching a functional cure in chronic hepatitis B.

The primary categories of drugs for hepatitis B virus (HBV) capsid inhibitors consist of core protein allosteric modulators (CpAMs), capsid assembly modulators, and additional types. HBV capsid inhibitors, alternatively referred to as core protein allosteric modulators (CpAMs), function as antiviral compounds that interfere with the formation or stability of the viral capsid, thus preventing HBV replication and lowering viral levels. Relevant applications encompass chronic hepatitis B, acute hepatitis B, and further uses, with distribution occurring via hospital pharmacies, retail pharmacies, online pharmacies, and other channels. End users comprise hospitals, clinics, research institutes, and others.

Tariffs are impacting the hbv capsid inhibitors market by increasing costs of imported active pharmaceutical ingredients, specialized chemical intermediates, biologic reagents, and clinical trial supplies. North America and Europe are most affected due to reliance on imported high-value drug substances and research materials, while Asia-Pacific faces cost pressure on manufacturing scale-up and export-oriented production. These tariffs are increasing development expenses and extending commercialization timelines. However, they are also encouraging regional manufacturing investments, localized clinical supply chains, and strategic collaborations to strengthen domestic antiviral drug production.

The hepatitis b virus (hbv) capsid inhibitors market research report is one of a series of new reports from The Business Research Company that provides hepatitis b virus (hbv) capsid inhibitors market statistics, including hepatitis b virus (hbv) capsid inhibitors industry global market size, regional shares, competitors with a hepatitis b virus (hbv) capsid inhibitors market share, detailed hepatitis b virus (hbv) capsid inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis b virus (hbv) capsid inhibitors industry. This hepatitis b virus (hbv) capsid inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis b virus (hbv) capsid inhibitors market size has grown rapidly in recent years. It will grow from $0.52 billion in 2025 to $0.59 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to global burden of chronic hepatitis b infection, limitations of existing antiviral therapies, early clinical validation of capsid inhibitors, increased virology research funding, growing pharmaceutical pipeline activity.

The hepatitis b virus (hbv) capsid inhibitors market size is expected to see rapid growth in the next few years. It will grow to $0.98 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to expansion of combination regimens with immunotherapies, rising investment in curative hbv treatments, increasing regulatory approvals for novel antivirals, growing global screening programs, advancement of next-generation capsid inhibitors. Major trends in the forecast period include increasing focus on functional cure strategies for hbv, rising development of capsid assembly modulators, growing combination therapy approaches, expansion of late-stage clinical pipelines, enhanced targeting of viral replication pathways.

The rising incidence of hepatitis B virus infections is anticipated to drive expansion in the hepatitis B virus (HBV) capsid inhibitors market. Hepatitis B virus (HBV) infections are liver conditions triggered by the hepatitis B virus, which can cause acute and chronic illnesses; they spread via contact with infected blood or bodily fluids, potentially leading to severe issues like liver cirrhosis or cancer. The growing prevalence of HBV infections stems primarily from insufficient vaccination rates, leaving significant segments of the population vulnerable and facilitating easier transmission through exposure to contaminated blood or fluids. Hepatitis B virus (HBV) capsid inhibitors combat these infections by interfering with viral capsid formation and assembly, which halts replication and curbs the virus's spread inside the body. For instance, in April 2024, a World Health Organization (WHO) report from the Switzerland-based intergovernmental body revealed that, as of late 2022, just 13% of people with chronic hepatitis B had received a diagnosis, while roughly 3% (7 million) were on antiviral treatment. For hepatitis C, 36% had been diagnosed, with 20% (12.5 million) accessing curative therapy-numbers well short of the 2030 global goal to treat 80% of those with chronic hepatitis B and C. Thus, the surge in hepatitis B virus infections is fueling demand for the hepatitis B virus (HBV) capsid inhibitors market.

Major companies in the hepatitis B virus (HBV) capsid inhibitors market are prioritizing innovations like oral small-molecule capsid assembly modulators to boost antiviral effectiveness, enhance patient adherence, and deliver long-term viral control. Oral small-molecule capsid assembly modulators are orally delivered antiviral drugs that disrupt the formation of the HBV capsid, preventing replication and lowering viral levels in the body. For example, in July 2024, Aligos Therapeutics, Inc., a U.S.-based clinical-stage biopharmaceutical firm, partnered with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company, to initiate a clinical trial assessing novel therapies for chronic hepatitis B (CHB), utilizing its cutting-edge capsid assembly modulator technology to improve antiviral performance and speed up next-generation HBV treatment development. This initiative represents a key milestone in Aligos's efforts to create potent and possibly curative options for chronic hepatitis B patients.

In October 2023, Gilead Sciences Inc., a US-based biopharmaceutical company, collaborated with Assembly Biosciences Inc. to combine its antiviral expertise with Assembly Biosciences Inc.'s advanced capsid inhibitor technology, speeding up the creation of next-generation small-molecule antivirals. These antivirals aim to boost viral suppression, enhance treatment results, and possibly deliver a functional cure for individuals with chronic hepatitis B infection. Assembly Biosciences Inc. is a US-based biotechnology company focused on discovering and developing antiviral therapeutics, including innovative agents against the hepatitis B virus (HBV) and other viral infections.

Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hepatitis b virus (hbv) capsid inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hepatitis B virus (HBV) capsid inhibitors market consists of sales of vebicorvir, bepirovirsen, cavrotolimod, hepcludex, and morphothiadin. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis B Virus (HBV) Capsid Inhibitors Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses hepatitis b virus (hbv) capsid inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis b virus (hbv) capsid inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hepatitis b virus (hbv) capsid inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Core Protein Allosteric Modulators (CpAMs); Capsid Assembly Modulators; Other Drug Types
• 2) By Application: Chronic Hepatitis B; Acute Hepatitis B; Other Applications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 4) By End-User: Hospitals; Clinics; Research Institutes; Other End-Users
• Subsegments:
• 1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs); Class II Core Protein Allosteric Modulators (CpAMs)
• 2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators; Indirect Capsid Assembly Modulators
• 3) By Other Drug Types: Novel Capsid Inhibitors; Combination Therapies; Experimental Mechanism-Based Inhibitors
• Companies Mentioned: Johnson & Johnson; Roche Holding AG; GlaxoSmithKline plc; Gilead Sciences Inc.; Jiangsu Hengrui Pharmaceuticals Co. Ltd.; Novotech Health Holdings Pte. Ltd; Enanta Pharmaceuticals Inc.; Assembly Biosciences Inc.; Arbutus Biopharma Corporation; Aligos Therapeutics Inc.; Qilu Pharmaceutical Co Ltd.; Chia Tai Tianqing Pharmaceutical Group Co Ltd.; Hepion Pharmaceuticals Inc.; Shanghai Zhimeng Biopharma Inc.; Antios Therapeutics; Bluejay Therapeutics Inc.; Core Biopharma Inc.; Door Pharmaceuticals; Shanghai Longwood Biopharmaceuticals Co. Ltd.; Zhimeng Biopharma Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Hepatitis B Virus (HBV) Capsid Inhibitors Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Hepatitis B Virus (HBV) Capsid Inhibitors Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
• 4.2. Major Trends
  • 4.2.1 Increasing Focus On Functional Cure Strategies For Hbv
  • 4.2.2 Rising Development Of Capsid Assembly Modulators
  • 4.2.3 Growing Combination Therapy Approaches
  • 4.2.4 Expansion Of Late-Stage Clinical Pipelines
  • 4.2.5 Enhanced Targeting Of Viral Replication Pathways

5. Hepatitis B Virus (HBV) Capsid Inhibitors Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Research Institutes
• 5.4 Pharmaceutical Companies
• 5.5 Specialty Hepatology Centers

6. Hepatitis B Virus (HBV) Capsid Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Hepatitis B Virus (HBV) Capsid Inhibitors Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Hepatitis B Virus (HBV) Capsid Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Hepatitis B Virus (HBV) Capsid Inhibitors Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Hepatitis B Virus (HBV) Capsid Inhibitors Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Hepatitis B Virus (HBV) Capsid Inhibitors Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Hepatitis B Virus (HBV) Capsid Inhibitors Market Segmentation

• 9.1. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types
• 9.2. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chronic Hepatitis B, Acute Hepatitis B, Other Applications
• 9.3. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
• 9.4. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Research Institutes, Other End-Users
• 9.5. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Core Protein Allosteric Modulators (CpAMs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)
• 9.6. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Capsid Assembly Modulators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators
• 9.7. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors

10. Hepatitis B Virus (HBV) Capsid Inhibitors Market Regional And Country Analysis

• 10.1. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 11.1. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 12.1. China Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 13.1. India Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 14.1. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 15.1. Australia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 16.1. Indonesia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 17.1. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 18.1. Taiwan Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 19.1. South East Asia Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 20.1. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 21.1. UK Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 22.1. Germany Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 23.1. France Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 24.1. Italy Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 25.1. Spain Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 26.1. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 27.1. Russia Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 28.1. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 29.1. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 30.1. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 31.1. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 32.1. Brazil Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 33.1. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market

• 34.1. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Hepatitis B Virus (HBV) Capsid Inhibitors Market, Segmentation By Drug Type, Segmentation By Application, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Hepatitis B Virus (HBV) Capsid Inhibitors Market Regulatory and Investment Landscape

36. Hepatitis B Virus (HBV) Capsid Inhibitors Market Competitive Landscape And Company Profiles

• 36.1. Hepatitis B Virus (HBV) Capsid Inhibitors Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Hepatitis B Virus (HBV) Capsid Inhibitors Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Hepatitis B Virus (HBV) Capsid Inhibitors Market Company Profiles
  • 36.3.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Jiangsu Hengrui Pharmaceuticals Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Hepatitis B Virus (HBV) Capsid Inhibitors Market Other Major And Innovative Companies

• Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.

38. Global Hepatitis B Virus (HBV) Capsid Inhibitors Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Hepatitis B Virus (HBV) Capsid Inhibitors Market

40. Hepatitis B Virus (HBV) Capsid Inhibitors Market High Potential Countries, Segments and Strategies

• 40.1 Hepatitis B Virus (HBV) Capsid Inhibitors Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Hepatitis B Virus (HBV) Capsid Inhibitors Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Hepatitis B Virus (HBV) Capsid Inhibitors Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer